CLAIMS

1. A peptide ligand specific for the collagen binding site of MT1-MMP comprising a polypeptide comprising at least three cysteine residues, separated by at least two loop sequences, and a non-aromatic molecular scaffold which forms covalent bonds with the cysteine residues of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold~~.~~

~~2. The peptide ligand as defined in claim 1, wherein said loop sequences comprise 6 amino acids.~~

~~3. The peptide ligand as defined in claim 1 or claim 2, wherein said loop sequences comprise three cysteine residues separated by two loop sequences both of which consists of 6 amino acids.~~

~~4. The peptide ligand as defined in any one of claims 1 to 3~~, wherein the peptide ligand comprises an amino acid sequence selected from:

C_i-P-F/I/Y-D/S-W-H-T-C_{ii}-L-F-G-D/E-Y-T/S-C_{iii} (SEQ ID NO: 1)

wherein C_i, C_{ii} and C_{iii} represent first, second and third cysteine residues, respectively or a pharmaceutically acceptable salt thereof.

2~~5~~. The peptide ligand as defined in claim ~~4~~1, wherein the peptide ligand of C_i-P-F/I/Y-D/S-W-H-T-C_{ii}-L-F-G-D/E-Y-T/S-C_{iii} (SEQ ID NO: 1) is selected from:

CPYSWETCLFGDYRC (SEQ ID NO: 2);
CPFDWHTCLFGDYTC (SEQ ID NO: 3);
CPFDWHTCLFGEYSC (SEQ ID NO: 4);
CPIDWHTCLFGDYTC (SEQ ID NO: 5);
CPFSWHTCLFGEYSC (SEQ ID NO: 6):
CPFSWHTCLFGDYTC (SEQ ID NO: 7);
CPISWHTCLFGDYSC (SEQ ID NO: 8); and
CPYSWHTCLFGDYSC (SEQ ID NO: 9)~~;~~.

3. The peptide ligand as defined in claim 2, wherein the peptide ligand of C_i-P-F/I/Y-D/S-W-H-T-C_{ii}-L-F-G-D/E-Y-T/S-C_{iii} (SEQ ID NO: 1) is further selected from:

A-(SEQ ID NO: 2)-A (BCY1026);
A-(SEQ ID NO: 3)-A (BCY1057);

A-(SEQ ID NO: 4)-A (BCY1065);
A-(SEQ ID NO: 5)-A (BCY1067);
A-(SEQ ID NO: 6)-A (BCY1073);
A-(SEQ ID NO: 7)-A (BCY1074);
A-(SEQ ID NO: 8)-A (BCY1075); and
A-(SEQ ID NO: 9)-A (BCY1076).

~~6~~4. The peptide ligand as defined in ~~any one of~~ claim~~s~~ 1 or claim 2~~to 5~~, wherein the molecular scaffold is TATA.

~~7~~5. The peptide ligand as defined in claim ~~6~~4, wherein the molecular scaffold is TATA and the peptide ligand of C_i-P-F/I/Y-D/S-W-H-T-C_{ii}-L-F-G-D/E-Y-T/S-C_{iii} (SEQ ID NO: 1) is selected from:

A-(SEQ ID NO: 2)-A (BCY1026);
A-(SEQ ID NO: 3)-A (BCY1057);
A-(SEQ ID NO: 4)-A (BCY1065);
A-(SEQ ID NO: 5)-A (BCY1067);
A-(SEQ ID NO: 6)-A (BCY1073);
A-(SEQ ID NO: 7)-A (BCY1074);
A-(SEQ ID NO: 8)-A (BCY1075); and
A-(SEQ ID NO: 9)-A (BCY1076).

~~8~~6. The peptide ligand as defined in any one of claims 1 to ~~7~~5, wherein the pharmaceutically acceptable salt is selected from the free acid or the sodium, potassium, calcium, ammonium salt.

~~9~~7. The peptide ligand as defined in any one of claims 1 to ~~8~~6, wherein the MT1-MMP is human MT1-MMP.

~~10~~8. A drug conjugate comprising a peptide ligand as defined in any one of claims 1 to ~~9~~7, conjugated to one or more effector and/or functional groups.

~~11~~9. The drug conjugate as defined in claim ~~10~~8, conjugated to one or more cytotoxic agents.

~~12~~10. The drug conjugate as defined in claim ~~11~~9, wherein said cytotoxic agent is selected from MMAE or DM1.

~~13~~11. A pharmaceutical composition which comprises the peptide ligand of any one of claims 1 to ~~6~~9 or the drug conjugate of any one of claims ~~10~~8 to ~~12~~10, in combination with one or more pharmaceutically acceptable excipients.

~~14~~12. The pharmaceutical composition as defined in claim ~~13~~11, which additionally comprises one or more therapeutic agents.

~~15~~13. The drug conjugate as defined in any one of claims ~~10~~8 to ~~12~~10, for use in a therapy for ~~-~~preventing, suppressing or treating a disease or disorder mediated by MT1-MMP.

14. Use of the drug conjugate as defined in any one of claims 8 to 10 in the manufacture of a medicament for preventing, suppressing or treating a disease or disorder mediated by MT1-MMP in a subject.

15. The use of drug conjugate as defined in claim 14, wherein the disease or disorder mediated by MT1-MMP includes cancers.

16. The use of drug conjugate as defined in claim 14, wherein the disease or disorder mediated by MT1-MMP includes non-small cell lung carcinomas.